Opportunities for therapeutic antibodies directed at G-protein-coupled receptors

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

G protein-coupled receptors (GPCRs) are key drug targets. In this article, Marshall and colleagues discuss the progress made towards generating GPCR-targeting antibodies, including which antigen formats and antibody platforms have been most successful. They review the current pipeline and outline outstanding challenges in antibody generation.

Related collections

Most cited references 248

Record: found
Abstract: not found
Article: not found

Continuous cultures of fused cells secreting antibody of predefined specificity.

G Köhler, C Milstein (1975)

0 comments Cited 506 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

A comprehensive map of molecular drug targets

Rita Santos Ferreira, Oleg Ursu, Anna Gaulton … (2017)

The success of mechanism-based drug discovery depends on the definition of the drug target. This definition becomes even more important as we try to link drug response to genetic variation, understand stratified clinical efficacy and safety, rationalize the differences between drugs in the same therapeutic

0 comments Cited 455 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Strategies and challenges for the next generation of antibody–drug conjugates

Alain Beck, Liliane Goetsch, Charles Dumontet … (2017)

Antibody–drug conjugate (ADCs), which aim to target highly cytotoxic drugs specifically to cancer cells, are one of the fastest growing classes of anticancer therapeutics, with more than 50 such agents currently in clinical trials. This Review discusses lessons learned and emerging strategies in the development of ADCs, including aspects such as target selection, the development of warheads, the optimization of linkers and new conjugation chemistries, and provides an overview of agents that are currently in clinical trials.